A common biotech security plan sounds responsible until someone examines it closely:
“We will strengthen security operations when we get closer to commercialization.”
What leadership is really saying is that the company will wait until the environment is larger, the data is more valuable, and the partner ecosystem is more complex before building the ability to detect and respond around the clock.
That is not thoughtful sequencing.
It is postponed accountability.
A pre-commercial biotech company may not need the same internal security headcount as a global pharmaceutical organization. It does need an operating model capable of recognizing a compromised identity, investigating the surrounding evidence, and acting before normal business hours return.
Your Internal IT Team Cannot Be the Entire Response Model
Most biotechnology IT teams working inside companies under $100 million in revenue are overloaded.
The same people may manage cloud platforms, endpoints, vendors, onboarding, laboratory connectivity, backups, compliance requests, user support, and executive emergencies.
Leadership then quietly adds another obligation:
Keep watch 24 hours a day.
That expectation is operationally dishonest.
Being “on call” is not the same as maintaining a staffed security operation.
A phone notification does not guarantee someone will wake up, understand the event, correlate several tools, determine severity, follow an approved runbook, document the investigation, and contain the threat within a defined period.
The team may possess the technical skill to respond.
What it lacks is continuous capacity.
When the security model depends on specific people always being available, the company has created key-person risk inside its threat-response process.
A Realistic After-Hours Failure
Consider a composite scenario common to cloud-first research companies.
At 1:12 a.m., a scientist’s identity signs into a cloud application from a new location. Minutes later, the account begins accessing shared repositories and downloading files.
A mailbox rule is added.
An authentication method changes.
Each platform records part of the story. None sees the entire story.
The endpoint platform does not identify malware because the attacker is using legitimate credentials. The identity system marks the login as suspicious but does not automatically disable the user. The SIEM creates an alert, but it enters a queue no one actively monitors overnight.
At 8:05 a.m., the internal team begins reviewing what happened.
The question is no longer:
“Can we stop this login?”
It becomes:
“What did the attacker access during the last seven hours?”
That shift from containment to reconstruction interrupts research, expands legal review, consumes leadership attention, and creates uncertainty about intellectual property exposure.
The failure was not the absence of another security product.
It was the absence of an accountable response model.
Maturity Means Decisions Are Made Before the Incident
Organizations often measure security maturity by the number of tools deployed or policies approved.
Those are inputs.
Operational maturity becomes visible when an incident occurs.
A mature model answers difficult questions in advance:
- Which identity, endpoint, email, cloud, and privileged-access events are monitored?
- Which events require immediate investigation?
- What response time applies to critical alerts?
- Who can disable an account, isolate a device, or revoke an active session?
- When must executives or legal counsel become involved?
- What evidence must be preserved?
- How will the organization prove what happened?
The NIST Cybersecurity Framework 2.0 treats governance, detection, response, and recovery as connected outcomes rather than isolated technical activities. HHS cybersecurity guidance for the healthcare and public-health sector also emphasizes security operations, incident response, centralized log collection, and rehearsed incident planning.
The lesson for biotech leadership is straightforward:
Buying detection without building response is incomplete security.
Managed Security Is Not a Shortcut
Some executives resist managed security services because they believe a serious company should eventually build everything internally.
That belief confuses ownership with labor.
The company must own its risk decisions, security priorities, containment authority, and executive accountability.
It does not have to employ every analyst needed to monitor alerts at 2:00 a.m., on weekends, during holidays, and while internal employees handle other priorities.
A managed or co-managed security model can combine internal business knowledge with external operating capacity.
The internal team understands the company’s science, applications, users, partners, and priorities. The managed security team supplies continuous monitoring, investigation experience, documented escalation, and contracted response expectations.
That is not replacing the IT director.
It is removing an unreasonable dependency on the IT director.
Strong managed security models do more than forward alerts. They investigate, correlate evidence, assign severity, follow approved escalation paths, contain threats where authorized, and document their actions.
Leadership should receive an investigation record not a vague notification that something suspicious occurred six hours earlier.
Seven Criteria for Evaluating the Model
- Real 24/7 Coverage
Ask who is actively monitoring at 2:00 a.m.
“The platform runs 24/7” is not an acceptable answer. Software availability is not analyst coverage.
- Defined Response Commitments
Look for contracted acknowledgement and investigation targets based on severity.
A 15- or 30-minute target matters only when staffing, escalation procedures, and reporting support it.
- Identity-Centered Investigation
Confirm that analysts can correlate identity activity with endpoint, email, cloud, VPN, and privileged-access evidence.
Identity compromise rarely stays inside one dashboard.
- Documented Containment Authority
Decide what the security team may disable or isolate, what requires approval, and who must be reached when primary leaders are unavailable.
Do not wait until an incident to negotiate permission.
- Evidence and Reporting
Require records of investigation steps, decisions, escalation times, containment actions, and remediation recommendations.
The provider should be able to explain what happened not merely prove that an alert was sent.
- Biotech Operating Awareness
A research repository, laboratory-connected asset, executive mailbox, and commercialization platform do not carry the same business consequence.
The response model must understand the difference.
- Validation Before Launch
Test the model through tabletop exercises and realistic after-hours scenarios.
An incident-response plan that has never been exercised is still an assumption.
Assess the Operating Model, Not the Product Stack
The security assessment that matters before commercialization is not a checklist of purchased products.
It tests whether the company can detect, investigate, escalate, contain, and explain an after-hours identity compromise.
Leadership should know where coverage stops, where authority becomes unclear, and where the response depends on one person being awake.
A security operations assessment can expose those gaps before an attacker, partner, insurer, investor, or board member does.
The company does not need to imitate a global pharmaceutical organization.
It needs a security operating model credible enough to support the company it is trying to become.
Commercialization is not the time to begin building that credibility.
It is the moment leadership will be expected to prove it already exists.
About Single Point of Contact
Single Point of Contact is an experienced MSP in the biotech industry and is a valuable partner, providing specialized knowledge in implementing robust backup strategies and ensuring network security and stability. With deep understanding of regulatory requirements such as HIPAA and FDA’s 21 CFR Part 11, Single Point of Contact safeguards sensitive research data, clinical trial information, and intellectual property. They offer tailored solutions, including automated backups, real-time monitoring, and disaster recovery plans, minimizing downtime and data loss. By managing security protocols, they protect against cyber threats, allowing biotech companies to focus on innovation while ensuring compliance and uninterrupted operations. This expertise enhances productivity and reduces risk. Contact us today to discover more about how we can help your biotech firm with DR, backup and security.
Biotech Podcast
On this podcast, we discuss data recovery. This episode explores the significant challenges biotech firms face in developing effective data recovery strategies. Topics include the importance of regular testing, rapid restoration capabilities, and the risks of inadequate planning. It highlights how speed and efficiency are crucial to uninterrupted operations, regulatory compliance, and maintaining trust in a data-driven industry. Tune in to the discussion.
Biotech YouTube
Subscribe to our YouTube channel. On a recent episode,” The Delay That Destroys Biotech”, Most biotech breaches aren’t discovered for months. And by the time they are, the damage is already done. In this episode, we break down what really happens during that silent window and why detection time, not prevention, defines your risk. If you can’t see it early, you can’t control it.
